Claims for Patent: 8,951,776

Summary for Patent: 8,951,776

Title:	Engineered microbes and methods for microbial oil production
Abstract:	Some aspects of this invention provide engineered microbes for oil production. Methods for microbe engineering and for use of engineered microbes are also provided herein. In some embodiments, microbes are provided that are engineered to modulate a combination of rate-controlling steps of lipid synthesis, for example, a combination of a step generating metabolites, acetyl-CoA, ATP or NADPH for lipid synthesis (a push step), and a step sequestering a product or an intermediate of a lipid synthesis pathway that mediates feedback inhibition of lipid synthesis (a pull step). Such push-and-pull engineered microbes exhibit greatly enhanced conversion yields and TAG synthesis and storage properties.
Inventor(s):	Stephanopoulos; Gregory (Winchester, MA), Tai; Mitchell (Seattle, WA), Chakraborty; Sagar (Cambridge, MA)
Assignee:	Massachusetts Institute of Technology (Cambridge, MA)
Application Number:	13/656,086
Patent Claims:	1. An isolated oleaginous yeast cell, comprising a genetic modification that increases expression of a diacylglycerol acyltransferase (DGA1) gene product and an acetyl-CoA carboxylase (ACC1) gene product, wherein the genetic modification comprises a first nucleic acid construct comprising an expression cassette comprising a coding nucleic acid encoding the DGA1 gene product; and a second nucleic acid construct comprising an expression cassette comprising a coding nucleic acid encoding the ACC 1 gene product; wherein the first nucleic acid construct and the second nucleic acid construct further comprises an intron-enhanced promoter that comprises a promoter sequence, a transcription start site, and an intronic sequence downstream of the transcription start site, and wherein the promoter is a translation elongation factor-1.alpha. (TEF) promoter. 2. The isolated oleaginous yeast cell of claim 1, further comprising a genetic modification that increases expression of a stearoyl-CoA-desaturase (SCD) gene product and/or of an ATP-citrate lyase (ACL) gene product, wherein the genetic modification comprises a nucleic acid construct comprising an expression cassette comprising a coding nucleic acid encoding the SCD and/or ACL gene product or an expression cassette comprising an intron-enhanced promoter that comprises a promoter sequence, a transcription start site, and an intronic sequence downstream of the transcription start site; and a coding nucleic acid encoding the SCD and/or ACL gene product. 3. The isolated oleaginous yeast cell of claim 1, wherein the first nucleic acid construct and/or the nucleic acid construct cassette comprises a suitable homologous or heterologous promoter. 4. The isolated oleaginous yeast cell of claim 1, wherein the increased expression of the gene product confers a beneficial phenotype for the conversion of a carbon source to a fatty acid, fatty acid derivative and/or triacylglycerol (TAG) to the cell, and wherein the beneficial phenotype comprises a modified fatty acid profile, a modified TAG profile, an increased fatty acid and/or triacylglycerol synthesis rate, an increase conversion yield, an increased triacylglycerol accumulation in the cell, and/or an increased triacylglycerol accumulation in a lipid body of the cell. 5. The isolated oleaginous yeast cell of claim 4, wherein the synthesis rate of a fatty acid or a TAG of the cell is at least 2-fold increased as compared to unmodified cells of the same cell type. 6. The isolated oleaginous yeast cell of claim 4, wherein the cell converts a carbon source to a fatty acid or a TAG at a conversion rate within the range of about 0.025 g/g to about 0.32 g/g (g TAG produced/g Glucose consumed), or at a conversion rate of at least 0.11 g/g. 7. A culture, comprising the oleaginous yeast cell of claim 1. 8. The culture of claim 7, further comprising a carbon source. 9. The culture of claim 8, wherein the carbon source comprises a fermentable sugar, an organic acid, and/or acetate. 10. The culture of claim 7, wherein the culture comprises glycerol. 11. The culture of claim 7, wherein the culture comprises ammonium sulfate. 12. A method, comprising contacting a carbon source with the isolated oleaginous yeast cell of claim 1; and incubating the carbon source contacted with the cell under conditions suitable for at least partial conversion of the carbon source into a fatty acid or a triacylglycerol by the cell. 13. The method of claim 12, wherein the oleaginous yeast cell further comprises a genetic modification that increases expression of an SCD gene product and/or an ACL gene product. 14. The isolated oleaginous yeast cell of claim 1, wherein the yeast is Yarrowia lipolytica or is derived from Yarrowia lipolytica. 15. The isolated oleaginous yeast cell of claim 1, wherein the coding nucleic acid encoding the DGA1 gene product comprises the nucleic acid sequence of SEQ ID NO: 1. 16. The isolated oleaginous yeast cell of claim 1, wherein the coding nucleic acid encoding the DGA1 gene product encodes for a protein comprising the amino acid sequence of SEQ ID NO: 2. 17. The isolated oleaginous yeast cell of claim 1, wherein the coding nucleic acid encoding the ACC1 gene product comprises the nucleic acid sequence of SEQ ID NO: 3. 18. The isolated oleaginous yeast cell of claim 1, wherein the coding nucleic acid encoding the ACC1 gene product encodes for a protein comprising the amino acid sequence of SEQ ID NO: 4.

Details for Patent 8,951,776

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2031-10-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2031-10-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2031-10-19